Intention-to-Treat Analysis but for Treatment Intention: How should Consumer Product Randomized Controlled Trials be Analyzed?


Authored by  R Weitkunat, G Baker, F Lüdicke

Published in International Journal of Statistics in Medical Research     

www.lifescienceglobal.com/component/content/article/91-abstract/ijsmr/2303-abstract-intention-to-treat-analysis-but-for-treatment-intention-how-should-consumer-product-randomized-controlled-trials-be-analyzed 

Abstract:

Background: Experimental study design, randomization, blinding, control, and the analysis of such data according to the intention-to-treat (ITT) principle are de-facto “gold standards” in pharmacotherapy research. While external treatment allocation under conditions of medical practice is conceptually reflected by in-study randomization in randomized controlled trials (RCTs) of therapeutic drugs, actual product use is based on self-selection in a consumer product setting.

Discussion: With in-market product allocation being consumer-internal, there is no standard against which protocol adherence can be attuned, and the question arises, as to whether compliance-based analysis concepts reflect the real-world effects of consumer products.

Summary: The lack of correspondence between RCTs and consumer market conditions becomes evident by the fact that even if, theoretically, all data would be available from all members of the real-world target population, it would be impossible to calculate either an ITT or a per-protocol effect. This renders the calculation of such estimates meaningless in consumer product research contexts.  

Our Findings

We are committed to sharing our results as the development and scientific assessment of our products advance. Read our most important findings with supporting peer-reviewed articles, presentations, and registered clinical trials.

What we have learned so far...